<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00803621</url>
  </required_header>
  <id_info>
    <org_study_id>I07009</org_study_id>
    <nct_id>NCT00803621</nct_id>
  </id_info>
  <brief_title>Cerebral Toxoplasmosis and AIDS</brief_title>
  <acronym>TOXODFA</acronym>
  <official_title>Cerebral Toxoplasmosis and AIDS in the French Departments of America (DFA). Diagnostic Contribution of a PCR Assay and Genetic Diversity of Toxoplasma Gondii.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With a HIV incidence much higher in the DFA than in European French territory, this disease
      is a major public health problem in these areas, especially in French Guiana.

      Cerebral toxoplasmosis is a priority among the opportunistic infections in AIDS patients from
      the DFA because of its frequency (French West Indies) and of its lethality (French Guiana).

      The diagnosis of cerebral toxoplasmosis may be difficult because based only on presumptive
      clinical and radiological features. The response to specific antitoxoplasmic therapy confirms
      a posteriori the diagnosis.

      In reference to the data collected by the Biological Resource Centre Toxoplasma, in
      particular in French Guiana, we think that T. gondii strains reactivating in AIDS patients
      from DFA are genetically different from those reactivating in AIDS patients from Europe, with
      an increased capacity for dissemination via peripheral blood in the first ones. This more
      frequent or more prolonged parasitemia could facilitate the diagnosis of cerebral
      toxoplasmosis by PCR test from peripheral blood samples in AIDS patients from the French
      departments of America.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <secondary_outcome>
    <measure>Isolation, genetic typing and storage of T. gondii strains collected among AIDS patients with cerebral toxoplasmosis from the DFA.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">46</enrollment>
  <condition>Cerebral Toxoplasmosis</condition>
  <condition>AIDS</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Toxoplasma PCR assay</intervention_name>
    <description>Toxoplasma PCR assay</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        AIDS patients from the French West Indies and French Guiana having clinical and
        radiological suspicion of cerebral toxoplasmosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patient (&gt; 18 years)

          -  Patient being informed and accepting to participate in the study with signature of
             informed consent

          -  HIV positive serology

          -  Clinical and radiological suspicion of cerebral toxoplasmosis justifying the start of
             specific antitoxoplasmic therapy

        Exclusion Criteria:

          -  Protected patient

          -  Patient uncovered by social insurance

          -  Specific antitoxoplasmic therapy already initiated since 72h or more
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel AJZENBERG, PharmD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CHU Limoges</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses - CHU de Pointe à Pitre</name>
      <address>
        <city>Pointe à Pitre</city>
        <state>Guadeloupe</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Services Maladies Infectieuses et Tropicales- CHU Fort-de-France</name>
      <address>
        <city>Fort-de-France</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologie et CISIH- CH Andrée Rosemon</name>
      <address>
        <city>Guyane-Française</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maladies Infectieuses et Tropicales - CH Andrée Rosemon</name>
      <address>
        <city>Guyane-Française</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Médecine- CH Ouest Guyanais</name>
      <address>
        <city>Guyane-Français</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <last_update_submitted>March 22, 2014</last_update_submitted>
  <last_update_submitted_qc>March 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Toxoplasmosis</mesh_term>
    <mesh_term>Toxoplasmosis, Cerebral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

